What is the dosing for KOVALTRY®?

KOVALTRY® offers the potential for 2x/week or 3x/week dosing in adolescents and adults, and 2x/week, 3x/week, or every‑other‑day dosing in children1

The recommended prophylaxis dose for adolescents and adults is 20 to 40 IU/kg 2x/week or 3x/week.1

The recommended prophylaxis dose for children 12 years old or younger is 25 to 50 IU/kg 2x/week, 3x/week, or every-other-day according to individual requirements.1

Talk to your doctor to find the right dose and treatment schedule for you.

KOVALTRY® comes in a wide range of vial sizes1

KOVALTRY®, Antihemophilic Factor (Recombinant), Dosing Info – Vial Sizes

250 IU, 500 IU, and 1000 IU with 2.5 mL prefilled diluent syringe

2000 IU and 3000 IU with 5.0 mL prefilled diluent syringe

Download the Discussion Guide to help plan a conversation with your doctor about your treatment goals


KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.

KOVALTRY® is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY® can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY® when you have surgery.

KOVALTRY® is not used to treat von Willebrand Disease.


You should not use KOVALTRY® if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY®.

Tell your healthcare provider if you have heart disease or are at risk for heart disease.

The common side effects of KOVALTRY® are headache, fever, and itchy rash.

Allergic reactions may occur with KOVALTRY®. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.

Your body can also make antibodies, called "inhibitors," against KOVALTRY®, which may stop KOVALTRY® from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.

Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY®.

For additional important risk and use information, please see full Prescribing Information.

Reference: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2016.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© 2018 Bayer. All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.

Access Services by Bayer is a trademark of Bayer.

Site Last Modified 04/2020